论文部分内容阅读
目的:探讨文拉法辛治疗前后重性抑郁障碍(major depressive disorder，MDD)患者血清超敏C反应蛋白(hypersensitive C-reactive protein，hs-CRP)、肿瘤坏死因子α(tumor necrosis factor α，TNF-α)、白介素-6(interleukin6，IL-6)水平的变化。方法:纳入35例MDD患者(患者组)和30名种族、性别、年龄、BMI、利手、受教育程度等匹配的健康对照者(对照组)。使用17项汉密尔顿抑郁量表(Hamilton depression scale，HAMD-17)和杨氏躁狂量表(Young manic rating scale，YMRS)评估患者情绪改变，以及文拉法辛治8周后的疗效。采用免疫比浊法测定血清hs-CRP水平，采用酶联免疫吸附实验测定血清TNF-α及IL- 6水平。采用n t检验比较患者组与对照组间炎性细胞因子水平的差异，对患者组治疗前后炎性细胞因子水平的变化与临床症状关系进行偏相关分析。n 结果:MDD组治疗前血清hs-CRP、TNF-α、IL-6的水平与对照组相比差异无统计学意义(n P>0.05)；治疗后HAMD-17评分[(5.63±2.81)分]较治疗前明显降低[( 22.49±4.48)分，n t＝14.40，n P<0.01)]，但仍高于对照组[(3.15±1.11)分，n t＝3.681，n P<0.01)]。患者治疗后血清hs-CRP[(0.37±0.43)mg/L，(0.88±0.97)mg/L，n t＝3.097，n P＝0.006]、TNF-α[(16.30±6.14)ng/L，(47.30±24.00)ng/L，n t＝6.495，n P<0.001]及IL-6水平[(4.70±2.30)ng/L，(6.47±4.07)ng/L，n t＝4.758，n P<0.001]显著低于治疗前。MDD组治疗后血清hs-CRP (n t＝－3.521，n P<0.05)、TNF-α (n t＝－7.744，n P<0.001)及IL-6 (n t＝－3.337，n P0.05). After treatment for 8 weeks, the score of HAMD-17 in MDD group was significantly decreased compared with that in pretreatment((5.63±2.81), (22.49±4.48),n t=14.40, n P<0.01), however were still higher than that in HC group ((3.15±1.11),n t=3.681, n P<0.01). Serum levels of hs-CRP ((0.37±0.43)mg/L, (0.88±0.97)mg/L,n t=3.097, n P=0.006), TNF-α ((0.37±0.43)ng/L, (0.88±0.97)ng/L,n t=3.097, n P=0.006) and IL-6 ((4.70±2.30)ng/L, (6.47±4.07)ng/L, n t=4.758, n P<0.001) in post-treatment were significant lower than those in pretreatment for MDD patients.Serum level of hs-CRP (n t=-3.521, n P<0.05), TNF-α (n t=-7.744, n P<0.001) and IL-6(n t=-3.337, n P<0.05) in post-treatment MDD group were significantly lower than those in HC group.After controlling for age and BMI, partial correlation analysis showed that TNF-α level was negatively correlated with duration of disease in the MDD group before(n r=-0.784, n P=0.012) and after treatment(n r=-0.658, n P=0.020).n Conclusion:Venlafaxine can reduce serum TNF-α, IL-6 and hs-CRP levels in patients with MDD, suggesting that changes in inflammatory cytokines may be involved in the mechanism of antidepressant therapy by venlafaxine.